Baudax gains on positive interim analysis of study data on muscle relaxant drug

Baudax Bio

24/01/2023 16:16

** Shares of drug developer Baudax Bio Inc  BXRX.O  surge
about 49% to $4.70
    ** Co reports positive outcome from its first interim
analysis of a mid-stage trial of its drug, BX1000, being tested
for use as a neuromuscular blockade (NMB) in patients undergoing
elective surgery
    ** All 20 patients in the cohort met the criteria for 'good'
or 'excellent' intubating conditions at 60 seconds - BXRX
    ** BXRX says the study treatments were generally well
tolerated with no occurrence of severe or serious adverse events
    ** Co says BX1000, combined with its reversal agent  BX3000,
could help patients emerge far more quickly from anesthesia  
    ** NMBs, or muscle relaxants, are used at the beginning of
surgery to help doctors insert a breathing tube
    ** Co says the trial comparing three different doses of
BX1000 to a standard dose of rocuronium, a anesthesia drug, is
planned to enroll a total of 80 adult patients undergoing
elective surgery
    ** Enrollment in the study expected to complete in Q1 and
topline data anticipated in April 2023
    ** BXRX shares fell nearly 99% in 2022 
 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))